Evidence map›Paper›PMID 42183944›Full record

ArticleJournal of autism and developmental disorders2026

Insight into Haploinsufficiency of the ERBB4 Gene: Expanding the Spectrum of Associated Phenotypes.

Irene Mademont-Soler, Maria Camós-Carreras, Aurore Garde, A Micheil Innes, Dijana Perovic, Barbara Golob, Aida Palacín, Henry Joel Mroczkowski, Kameryn M Butler, Paulien Van Galen and 27 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of autism and developmental disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Irene Mademont-SolerÀrea de Genètica Clínica i Consell Genètic, Laboratori Clínic Territorial ICS Girona, Hospital Universitari de Girona Dr. Josep Trueta, Av.França S/N, 17007, Girona, Spain. imademont.girona.ics@gencat.cat.ORCID http://orcid.org/0000-0002-6501-9250
Maria Camós-CarrerasGrup de Trastorns del Neurodesenvolupament, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI), Girona, Spain.
Aurore GardeCentre de Référence Anomalies du Développement Et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon, Dijon, France.
A Micheil InnesDepartments of Pediatrics and Medical Genetics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Dijana PerovicFaculty of Medicine, Institute of Human Genetics, University of Belgrade, Belgrade, Serbia.
Barbara GolobClinical Institute of Genomic Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Aida PalacínGrup de Trastorns del Neurodesenvolupament, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI), Girona, Spain.
Henry Joel MroczkowskiThe University of Tennessee Health Science Center, Memphis, USA.
Kameryn M ButlerGreenwood Genetic Center, Greenwood, SC, USA.
Paulien Van GalenDepartments of Pediatrics and Medical Genetics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Gabriela OpreaArcensus GmbH, Rostock, Germany.
Özge GüngörEGE University School of Medicine Medical Genetics, Izmir, Turkey.
Dolors Casellas-VidalGrup de Trastorns del Neurodesenvolupament, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI), Girona, Spain.
Gemma HernándezGrup de Trastorns del Neurodesenvolupament, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI), Girona, Spain.
Himanshu GoelHunter Genetics, Australia and the University of Newcastle, Callaghan, Australia.
Julia ApplebyLethbridge Outreach Genetic Services, Chinook Regional Hospital, Lethbridge, Alberta, Canada.
Ruzica KravljanacDepartment of Neurology, Mother and Child Health Care Institute of Serbia "Dr Vukan Cupic", Belgrade, Serbia.
Kenya De LeonGreenwood Genetic Center, Columbia, SC, USA.
Aboulfazl RadArcensus GmbH, Rostock, Germany.
Merve YavuzEGE University School of Medicine Neurology, Izmir, Turkey.
Najim AmezianeArcensus GmbH, Rostock, Germany.
Asude DurmazEGE University School of Medicine Medical Genetics, Izmir, Turkey.
Cristina PopescuAMS Laborator Genetic, Bucharest, Romania.
Ayça AykutEGE University School of Medicine Medical Genetics, Izmir, Turkey.
Haluk AkınEGE University School of Medicine Medical Genetics, Izmir, Turkey.
Figen GökçayEGE University School of Medicine Neurology, Izmir, Turkey.
Ioana MindrutaNeurology Department, University Emergency Hospital, Bucharest, Romania.
Brankica BosankicUniversity Children's Hospital, Belgrade, Serbia.
Renee PerrierDepartments of Pediatrics and Medical Genetics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
William BurnsGreenwood Genetic Center, Columbia, SC, USA.
Debra L HannaThe University of Tennessee Health Science Center, Memphis, USA.
Nela MaksimovicFaculty of Medicine, Institute of Human Genetics, University of Belgrade, Belgrade, Serbia.
Borut PeterlinClinical Institute of Genomic Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Bradley PrinceDepartments of Pediatrics and Medical Genetics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Hana SafraouUniversité Bourgogne-Franche Comté, Dijon, France.
Maria ObónÀrea de Genètica Clínica i Consell Genètic, Laboratori Clínic Territorial ICS Girona, Hospital Universitari de Girona Dr. Josep Trueta, Av.França S/N, 17007, Girona, Spain.
Susanna Esteba-CastilloGrup de Trastorns del Neurodesenvolupament, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI), Girona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe ERBB4 gene encodes a tyrosine kinase receptor for neuregulins and EGF family members, and plays a crucial role in various neurobiological processes. At present, the phenotypic manifestations of genetic variants that disrupt ERBB4 gene function (null variants) are not well established.

methodsA search for new patients with null variants in ERBB4 was initiated through an international data-sharing collaboration via GeneMatcher, and by searching the databases Decipher and ClinVar. Diagnosis had been performed using chromosomal microarray analysis, whole-exome sequencing, or whole-genome sequencing.

resultsTwenty-four new patients from 13 unrelated families with null variants in ERBB4 were identified. Genetic findings included single- or multiple-exon deletions in eight families, a reciprocal translocation disrupting ERBB4 in one family, and sequence variants in four. Variants arose de novo in four probands, were inherited in eight, and had an unknown inheritance pattern in one. Co-segregation of variants with clinical manifestations was observed within families. The predominant clinical features included neurodevelopmental disorders (intellectual disability, neurodevelopmental delay, autism spectrum disorder, and attention deficit hyperactivity disorder), speech delay, challenging behaviors, hypotonia, psychiatric conditions and seizures.

conclusionThis study represents the largest case series of patients with neurological disorders and null variants in the ERBB4 gene. Our findings support haploinsufficiency as the most plausible pathophysiological mechanism underlying ERBB4-related disorders and broaden the spectrum of associated phenotypes. Autism spectrum disorders and psychiatric manifestations have emerged as frequent, previously underrecognized features. Penetrance appears to be high but incomplete, and expressivity is highly variable, with a tendency toward intrafamilial phenotypic conservation.

Indexed as

2q34 deletionAutism spectrum disorderERBB4Gonadal mosaicismHaploinsufficiencyIntellectual disabilityNeurodevelopmental disordersPsychiatric disorders

Identifiers

PMID42183944

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.